A Salvat company

to Pharmaloop

What drives Pharmaloop

Mission, Vision
& Values

Pharmaceutical development,
delivery and manufacturing

The Company

More than 60 years of innovation


Since 1955

Our History

to Pharmaloop

Mission, Vision and Values

What Drives Pharmaloop

Pharmaloop strives to become a hub for the development of pharmaceutical, biotech and consumer health products, offering advanced manufacturing capabilities from early stage to market. Our calling is innovation.

Staffed by experienced industry experts, we offer product formulation for solids, semi-solids and liquids.

Our state-of-the-art facilities allow us to provide services for pilot, clinical trial material and commercial-scale manufacturing.



We staff smart, focused professionals who enjoy challenges and a collaborative yet forward-thinking work environment. We follow a process of continuous improvement in order to maintain the highest levels of safety, competitiveness and efficiency. Our clients engage us to develop pharmaceutical, biotech and consumer health products under the highest quality standards and we enjoy working on socially relevant projects. Our staff is extremely dedicated and is rewarded with competitive compensation and a progressive work environment.

Motivation fuelled by challenges

Our actions are directed towards seeking and successfully overcoming new challenges beyond the usual parameters of business. This is successful by setting ambitious objectives that involve exploring and creating new lines of growth and expansion.


Our conduct shall always be respectful towards people and the environment. We shall comply with our social, legal and environmental duties as professionals and responsible members of society as a whole.

Creativity and initiative

We aim to become innovators in all areas of activity in our daily work, anticipating events and requirements in a proactive manner, identifying options for growth and constantly proposing solutions and alternatives.

Development as a team

As a team, we aspire to acquire greater knowledge and skills by adopting a constant focus on personal and professional progress, and helping to ensure the growth of the Company.

Adaptation and flexibility

We stand prepared to accept and adapt to an evolving environment, to quickly modify our actions when the situation requires and to accept tasks and functions that are different to those which we normally perform.

We provide fully integrated services from formulation to development, clinical supply and niche commercial manufacturing. 

The Company

Pharmaceutical development, delivery and manufacturing

Salvat has more than 69 years of experience in drug development and manufacturing. Whether you are seeking an adapted solution or multiple services throughout your product’s lifecycle, we are here to help.

From early development and formulation, clinical supply and optimal dose form delivery to large scale commercial manufacturing, we can accelerate your path to market for oral sustained release, sterile solutions and suspensions. We also have extensive experience in consumer health products.


More than 69 years of innovation

Salvat is an independent pharmaceutical company, established in Barcelona, Spain in 1955. Today we are managed by the 3rd and 4th generation of the family. Our focus has always been on the development and commercialization of products that will positively change patient lives.

This has been the Salvat history and will continue to be the goal for our future. We believe in organic growth, with a long-term vision and a clear goal of continuous job creation. As a family business, the Salvat Group keeps ethics at the forefront of everything we do.

Salvat has offices in Barcelona, Madrid and Miami, where we also own manufacturing facilities. We have our own marketing and sales structure in Spain, Portugal, Central America and Sub-Saharan Africa, and partner with licensees to market our products in Europe, United States, Canada, Mexico, South America, North of Africa, Middle East, India, South East Asia, China and South Korea.

Today, with almost 500 employees in Spain, three spanish manufacturing plants in Barcelona and Madrid; and a production line of sterile liquids in Tamarac (Florida), two marketed products in the US and a broad international presence, we envision a great future for Salvat.

Visit Salvat website


Our history

Since 1955


Founded Laboratorios Salvat

Tomas Miarnau and Dr. Antonio Salvat founded the Company in Barcelona in 1955. Today Salvat is still a family business, led by the descendants of Jose Maria Peris Miarnau, lawyer and nephew of one of the founders, and Elvira Maria Teresa Musso Borras.


Launch of Salvacolina®

Salvacolina® became our first big brand. Dr. Montserrat invented the product, indicated for the symptomatic treatment of unspecific acute diarrhea.


Establishment of the Research, Synthesis and Development Department

This expansion allowed Salvat to achieve full vertical integration at a time when basic research and organic chemistry were the differentiating factors for growing pharmaceutical companies.


Cristalmina® (topical clorhexidine gluconate)

Cristalmina® is an OTC topical antiseptic, leader in the Spanish market and the flagship brand of Salvat.


Cetraxal® Otic (worldwide innovation ciprofloxacin otic solution)

With the launch of Cetraxal® Otic in the 90s we expanded to dominate the Spanish topical antibiotic market, and became a referent in the treatment of ear infections.


Monolitum® (Lansoprazole – own pellets technology)

Around our proprietary Orally Dispersible Tablet technology, we developed Monolitum®. Two decades later, it remains as the go-to product for acute treatment of duodenal ulcers, gastric ulcers and oesophagitis due to gastro-oesophageal reflux.


New R&D Center

With the new millennium we launched a new Research and Development center, primarily focused on pharmaceutical technologies.


Cetraxal® Plus (unique combination ciprofloxacin + fluocinolone otic solution)

Cetraxal® Plus became the first combination of this kind for the treatment of ear infections. With the launch of this product we were solidified as leaders in the otology field.


Ebernet® (New chemical entity: Eberconazole)

Our first new chemical entity to reach the market, Ebernet® is sold in 3 continents and we continue to expand its use in alternative indications.


SALVAT USA Inc. is founded. New offices in Miami, FL

With the opening of this wholly owned subsidiary we made a commitment to continue to grow and innovate in the US market.


Blow-Fill-Seal technology is introduced at our production facility

A decade ago we identified Blow-Fill-Seal (BFS) as the technology of the future for aseptic and preservative manufacturing. BFS would soon become the basis of our innovation and would allow us to develop leading products for international markets.


Malacur® launched in Africa

Malacur® has grown to be one of the go-to brands for the treatment of malaria in Africa. The product allowed us to expand our presence through various African territories.


FDA approval and US launch of Cetraxal® Otic in single use vials

A new star was born in 2009 with the launch of Cetraxal® Otic in the US. In combination with our Blow-Fill-Seal technology, we led the full development of the product to become the first Spanish pharmaceutical company with a marketed Rx product in the US.


Otovel® (ciprofloxacin + fluocinolone) partnerships and launches in multiple regions, including the USA

Shortly following the launch of our first product in the US, we launched the second, Otovel®. Its current and future indications have the potential to become the leading brand for the topical treatment of ear infections in the US.


New Blow-Fill-Seal manufacturing line in the USA

With our growing presence in the US, we identified the opportunity to own our first FDA-approved manufacturing facility. This expanded facility in the US will increase efficiency and will assist us with local innovation while offering contract manufacturing services to third parties.


Pharmaloop: Acquisition of new manufacturing site in Madrid

With the acquisition of Pharmaloop in Madrid we expanded our production capacity, and we established the foundation for the growth of our contract development and contract manufacturing businesses.